Estimation of the warfarin dose with clinical and pharmacogenetic data. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) N Engl J Med 360: 753-64 Genetic determinants of response to warfarin during initial anticoagulation. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) N Engl J Med 358: 999-1008 Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA (2013) Lancet 382: 790-6 Obesity-associated variants within FTO form long-range functional connections with IRX3. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gómez-Marín C, Aneas I, Credidio FL, Sobreira DR, Wasserman NF, Lee JH, Puviindran V, Tam D, Shen M, Son JE, Vakili NA, Sung HK, Naranjo S, Acemel RD, Manzanares M, Nagy A, Cox NJ, Hui CC, Gomez-Skarmeta JL, Nóbrega MA (2014) Nature 507: 371-5 Cytochrome P-450 3A4: regulation and role in drug metabolism. Guengerich FP (1999) Annu Rev Pharmacol Toxicol 39: 1-17 Structures of the multicomponent Rieske non-heme iron toluene 2,3-dioxygenase enzyme system. Friemann R, Lee K, Brown EN, Gibson DT, Eklund H, Ramaswamy S (2009) Acta Crystallogr D Biol Crystallogr 65: 24-33 Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, Ichikawa I (1997) J Clin Invest 99: 855-60 A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, Cai G, Sadikovic B, Lee K, Lo C, Gao K, Person RE, Moss TJ, German JR, Huang N, Shinawi M, Treadwell-Deering D, Szatmari P, Roberts W, Fernandez B, Schroer RJ, Stevenson RE, Buxbaum JD, Betancur C, Scherer SW, Sanders SJ, Geschwind DH, Sutcliffe JS, Hurles ME, Wanders RJ, Shaw CA, Leal SM, Cook EH, Goin-Kochel RP, Vaz FM, Beaudet AL (2012) Proc Natl Acad Sci U S A 109: 7974-81 Regulation of the induction of a cytochrome P-450 prostaglandin omega-hydroxylase by pregnancy in rabbit lung. Muerhoff AS, Williams DE, Leithauser MT, Jackson VE, Waterman MR, Masters BS (1987) Proc Natl Acad Sci U S A 84: 7911-4 Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Shimada T, Guengerich FP (1989) Proc Natl Acad Sci U S A 86: 462-5 Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Holla VR, Adas F, Imig JD, Zhao X, Price E, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH (2001) Proc Natl Acad Sci U S A 98: 5211-6 Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D (2009) Blood 113: 3925-30 Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB (2011) Blood 118: 3163-71 Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA (1987) Cancer Res 47: 5488-93 Inactivation of 1,3-, 1,6-, and 1,8-dinitropyrene by cytochrome P-450 enzymes in human and rat liver microsomes. Shimada T, Guengerich FP (1990) Cancer Res 50: 2036-43 Purification and characterization of xenobiotic-metabolizing enzymes from lung tissue. Guengerich FP (1990) Pharmacol Ther 45: 299-307 Use of array CGH to detect exonic copy number variants throughout the genome in autism families detects a novel deletion in TMLHE. Celestino-Soper PB, Shaw CA, Sanders SJ, Li J, Murtha MT, Ercan-Sencicek AG, Davis L, Thomson S, Gambin T, Chinault AC, Ou Z, German JR, Milosavljevic A, Sutcliffe JS, Cook EH, Stankiewicz P, State MW, Beaudet AL (2011) Hum Mol Genet 20: 4360-70 Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Thier R, Coles B, Harris TM (1994) Environ Health Perspect 102 Suppl 9: 49-53 Hypothalamic peptidyl-glycine alpha-amidating monooxygenase: preliminary characterization. Emeson RB (1984) J Neurosci 4: 2604-13 Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Schwarz UI, Stein CM (2006) Clin Pharmacol Ther 80: 7-12 Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Lang CC, Brown RM, Kinirons MT, Deathridge MA, Guengerich FP, Kelleher D, O'Briain DS, Ghishan FK, Wood AJ (1996) Clin Pharmacol Ther 59: 41-6 The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ (2011) Clin Pharmacol Ther 89: 408-15 Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ (1996) Clin Pharmacol Ther 59: 47-51 Formation of the indigo precursor indican in genetically engineered tobacco plants and cell cultures. Warzecha H, Frank A, Peer M, Gillam EM, Guengerich FP, Unger M (2007) Plant Biotechnol J 5: 185-91 Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Schneider C, Pratt DA, Porter NA, Brash AR (2007) Chem Biol 14: 473-88 Glucose and lactate biosensors for scanning electrochemical microscopy imaging of single live cells. Ciobanu M, Taylor DE, Wilburn JP, Cliffel DE (2008) Anal Chem 80: 2717-27 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Huang Z, Guengerich FP, Kaminsky LS (1998) Carcinogenesis 19: 867-72 Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. Guengerich FP, Sorrells JL, Schmitt S, Krauser JA, Aryal P, Meijer L (2004) J Med Chem 47: 3236-41 Human liver mephenytoin 4'-hydroxylase cytochrome P-450 proteins and genes. Brian WR, Ged C, Bellew TM, Srivastava PK, Bork RW, Umbenhauer DR, Lloyd RS, Guengerich FP (1989) Drug Metab Rev 20: 449-65 Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Park SK, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS (2003) Mol Cell Biol 23: 4959-71 The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. Sherman DH, Li S, Yermalitskaya LV, Kim Y, Smith JA, Waterman MR, Podust LM (2006) J Biol Chem 281: 26289-97 Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity. Keeney DS, Skinner C, Travers JB, Capdevila JH, Nanney LB, King LE, Waterman MR (1998) J Biol Chem 273: 32071-9 Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. Yamazaki H, Shimada T, Martin MV, Guengerich FP (2001) J Biol Chem 276: 30885-91 Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP (1996) J Biol Chem 271: 27438-44 Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. Bork RW, Muto T, Beaune PH, Srivastava PK, Lloyd RS, Guengerich FP (1989) J Biol Chem 264: 910-9 Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. Kim D, Wu ZL, Guengerich FP (2005) J Biol Chem 280: 40319-27 Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. Hanna IH, Krauser JA, Cai H, Kim MS, Guengerich FP (2001) J Biol Chem 276: 39553-61 Kinetic analysis of oxidation of coumarins by human cytochrome P450 2A6. Yun CH, Kim KH, Calcutt MW, Guengerich FP (2005) J Biol Chem 280: 12279-91 Beta-naphthoflavone induction of a cytochrome P-450 arachidonic acid epoxygenase in chick embryo liver distinct from the aryl hydrocarbon hydroxylase and from phenobarbital-induced arachidonate epoxygenase. Nakai K, Ward AM, Gannon M, Rifkind AB (1992) J Biol Chem 267: 19503-12 Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. Wu ZL, Podust LM, Guengerich FP (2005) J Biol Chem 280: 41090-100
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.